Stanford Graduate School of Business (USA)
-
Invitrogen (A)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209A-EStrategyFounded in 1987, Invitrogen was one of the largest catalog life science companies in the industry. Its customers came from academic research, biotechnology and pharmaceutical companies and government laboratories. Scientists viewed Invitrogen as a one-stop shop for all major molecular biology, biochemistry and cell culture reagent products, with prices ranging from a hundred dollars to a few thousand dollars.Starting at €8.20
-
Invitrogen/Life Technologies (B)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209B-EStrategyOn June 12, 2008, Invitrogen and Applied Biosystems announced plans to merge. The combined company was to be renamed Life Technologies (NASDAQ: LIFE). Invitrogen offered to acquire Applied Biosystems for $6.7 billion in cash and stock. AB shareholders would receive $38 per share in cash and stock, representing a 17 percent premium over the share’s closing price on Wednesday, June 11, 2008.Starting at €5.74
-
Gary Loveman and Harrah's Entertainment
Jeffrey Pfeffer, Victoria ChangCase SGSB-OB45-ELeadership and People ManagementIn 1998, 38-year-old Gary Loveman was perfectly content with his job as an untenured associate professor at the Harvard Business School (HBS). He was a popular teacher with standing room only classes in service management. He lived comfortably with his family in Massachusetts and had successful consulting engagements and executive education assignments with companies such as Harrah’s Entertainment. His prospects for his tenure review, coming up i...Starting at €8.20
-
First Solar, Inc. in 2013
Burgelman R; Siegel R; Hallmon MCase SGSB-SM190B-EStrategyAn update to First Solar (A), this case highlights changes to the solar energy market between 2010 and 2013 and the resulting challenges that First Solar had to overcome. In addition to increased competition from highly subsidized Chinese manufacturers, First Solar lost its pricing advantage due to a steep decline in material costs for the competing solar cell technology, c-Sci. The 2008 global financial crisis spurred a dramatic decline in de...Starting at €8.20
-
Invitrogen/Life Technologies (C): The "Best Owner" of the Asset
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209C-EStrategyThis short case discusses the process of Life Technologies’ acquisition by Thermo Fisher in 2013 and 2014. The case is a complement to SM-209A and SM-209B, which highlight the various growth and acquisition strategies the company undertook over the previous 10 years.Starting at €5.74